“Clinician- and Patient-Reported Outcomes with Tirbanibulin 1% Treatment for Actinic Keratosis in Routine Clinical Practice Across the U.S. (PROAK Study)” (2023) SKIN The Journal of Cutaneous Medicine, 7(3), pp. 771–787. doi:10.25251/skin.7.3.3.